These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30666669)

  • 1. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages.
    Thassakorn P; Patchanee P; Pongkan W; Chattipakorn N; Boonyapakorn C
    J Vet Pharmacol Ther; 2019 May; 42(3):258-267. PubMed ID: 30666669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
    Surachetpong S; Jiranantasak T; Rungsipipat A; Orton EC
    J Vet Cardiol; 2013 Sep; 15(3):171-80. PubMed ID: 23816827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
    Cunningham SM; Rush JE; Freeman LM
    J Vet Intern Med; 2013; 27(4):985-9. PubMed ID: 23758137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease.
    Hezzell MJ; Falk T; Olsen LH; Boswood A; Elliott J
    J Vet Cardiol; 2014 Dec; 16(4):257-64. PubMed ID: 25292459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease.
    Hezzell MJ; Boswood A; Chang YM; Moonarmart W; Elliott J
    Am J Vet Res; 2012 Nov; 73(11):1765-74. PubMed ID: 23106462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease.
    Winter RL; Saunders AB; Gordon SG; Buch JS; Miller MW
    J Vet Cardiol; 2017 Apr; 19(2):124-131. PubMed ID: 28111138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the understanding of the pathogenesis, progression and diagnosis of myxomatous mitral valve disease in dogs.
    Burchell RK; Schoeman J
    J S Afr Vet Assoc; 2014 Aug; 85(1):1101. PubMed ID: 25685978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
    Kim HS; Kang JH; Jeung EB; Yang MP
    J Vet Intern Med; 2016 Sep; 30(5):1589-1600. PubMed ID: 27573621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
    Mangklabruks T; Surachetpong SD
    J Vet Cardiol; 2014 Sep; 16(3):155-62. PubMed ID: 25127665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease.
    Chapel EH; Scansen BA; Schober KE; Bonagura JD
    J Vet Intern Med; 2018 Jan; 32(1):64-71. PubMed ID: 29224256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of granulocyte colony-stimulating factor in dogs with severe myxomatous mitral valve disease.
    Kang MH; Park HM
    Vet Q; 2014; 34(2):60-6. PubMed ID: 25252247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.
    Ljungvall I; Höglund K; Lilliehöök I; Oyama MA; Tidholm A; Tvedten H; Häggström J
    J Vet Intern Med; 2013; 27(5):1105-12. PubMed ID: 23865457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I; Olsen LH; Kvart C; Hoglund K; Moesgaard SG; Kamstrup TS; Pedersen HD; Häggström J
    Vet J; 2009 May; 180(2):195-201. PubMed ID: 18675567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.